ReviewNeurology international2022
Multiple Sclerosis Treatment in the COVID-19 Era: A Risk-Benefit Approach.
Paolo Immovilli et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
3 papers cite it
this papercites it
ReviewNeurology international2022
Paolo Immovilli et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.